Gorter, Thomas M.van Veldhuisen, Dirk J.Bauersachs, JohannBorlaug, Barry A.Celutkiene, JelenaCoats, Andrew J.S.Crespo-Leiro, María GenerosaGuazzi, MarcoHarjola, Veli-PekkaHeymans, StephaneHill, LoreenaLainscak, MitjaLam, Carolyn S.P.Lund, Lars H.Lyon, Alexander R.Mebazaa, AlexandreMueller, ChristianPaulus, Walter J.Pieske, Burkert MathiasPiepoli, MassimoRuschitzka, FrankRutten, Frans H.Seferovic, Petar M.Solomon, Scott D.Shah, Sanjiv J.Triposkiadis, FilipposWachter, RolfTschöpe, CarstenDe Boer, Rudolf A.2026-09-022026-09-022017-10-16Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJS, Crespo-Leiro MG, Guazzi M, Harjola VP, Heymans S, Hill L, Lainscak M, Lam CSP, Lund LH, Lyon AR, Mebazaa A, Mueller C, Paulus WJ, Pieske B, Piepoli MF, Ruschitzka F, Rutten FH, Seferovic PM, Solomon SD, Shah SJ, Triposkiadis F, Wachter R, Tschöpe C, de Boer RA. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management: position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018 Jan;20(1):16-37.1879-0844https://hdl.handle.net/2183/49128Review[Abstract] There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.engThis is a pre-copyedited, author-produced version of an article accepted for publication in European Journal of Heart Failure following peer review. The version of record is available online on the OUP website.BiomarkersHeart failureHeart failure with preserved ejection fractionPulmonary hypertensionRight ventricular functionjournal articleopen access10.1002/EJHF.1029